MedTrace Logo

A Thorough QT Study of TR-701free Acid (FA) in Healthy Subjects

NCT01461460 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2018-12-05

No results posted yet for this study

Summary

The purpose of this study is to assess the effects of oral TR-701 free acid (FA) versus placebo on QTcF.

Conditions

  • Healthy Volunteer

Interventions

DRUG

TR-701 FA 1200 mg

6 tablet of T-701 FA

DRUG

Moxifloxacin 400 mg

1 tablet 400 mg Moxifloxacin

DRUG

TR-701 FA 200 mg plus Placebo

1 tablet of TR-701 FA with 5 tablet placebo

DRUG

Placebo

6 placebo tablets

Sponsors & Collaborators

  • Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

    lead INDUSTRY

Principal Investigators

  • Philippe G Prokocimer, MD · Trius Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-11-28
Primary Completion
2011-12-23
Completion
2011-12-23

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01461460 on ClinicalTrials.gov